BioCentury | Sep 12, 2020
Product Development

Galapagos gains on Phase II win for systemic sclerosis candidate

...Data from the IPF trial are expected in 1H21. The systemic sclerosis readout comes days after Corbus Pharmaceuticals Holdings Inc....
...its primary and secondary endpoints in the Phase III RESOLVE-1 trial for the same indication. Corbus...
BioCentury | Sep 9, 2020
Product Development

Sept. 8 Quick Takes: Phase III wins for Albireo, Merck and Spero; plus Corbus, Blueprint, AnHeart, Grifols-Alkahest, and Exelixis-NBE

...to submit an NDA to FDA in 2Q21.Corbus’...
BioCentury | Jul 9, 2020
Management Tracks

Goeltz to join Arcus as CFO following Gilead deal; plus changes at Corbus, MyoKardia, Humanigen, Aimmune, Avrobio, Syndax and more

...in Gilead Deal” ). George Golumbeski joined the board of inflammatory and autoimmune diseases company Corbus Pharmaceuticals Holdings Inc....
BioCentury | Feb 1, 2019
Financial News

Corbus raises $35M follow-on

...Inflammatory and fibrotic diseases company Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) raised $35 million on Jan. 25 through the sale...
...10% discount to Corbus' close of $7.26 on Jan. 24, before the offering was announced. Corbus Pharmaceuticals Holdings Inc....
...close of $7.26 on Jan. 24, before the offering was announced. Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), Norwood, Mass. Shannon Lehnbeuter Corbus Pharmaceuticals Holdings Inc....
BioCentury | Sep 21, 2018
Company News

Corbus gets over 600 endocannabinoid-targeting compounds from Jenrin

...will receive $250,000 upfront and is eligible for $18.4 million in milestones for each compound Corbus...
...Jenrin will not research, develop or commercialize any compounds modulating cannabinoid receptors for 10 years. Corbus...
...and kidney diseases. Jenrin Discovery LLC, Chadds Ford, Pa. Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), Norwood, Mass. Business: Pharmaceuticals Jennie Walters Corbus Pharmaceuticals Holdings Inc. Jenrin...
BioCentury | Aug 11, 2018
Product Development

Exacerbation management

...Based on work spearheaded by the Cystic Fibrosis Foundation, Corbus Pharmaceuticals Holdings Inc. will be the first company to...
...FEV1) but did reduce the frequency of pulmonary exacerbations, the Cystic Fibrosis Foundation (CFF) suggested Corbus...
...gain in lung function is dramatic over the long term.” Yuval Cohen, Corbus Cohen said Corbus...
BioCentury | Aug 3, 2018
Clinical News

Celtaxsys planning Phase III program for CF candidate

...the North American Cystic Fibrosis Foundation meeting in Denver in October. In January, FDA gave Corbus Pharmaceuticals Holdings Inc....
...primary efficacy endpoint of a Phase IIb trial of its CF candidate lenabasum (formerly anabasum). Corbus...
BioCentury | Aug 2, 2018
Clinical News

Celtaxsys planning Phase III program for CF candidate

...the North American Cystic Fibrosis Foundation meeting in Denver in October. In January, FDA gave Corbus Pharmaceuticals Holdings Inc....
...primary efficacy endpoint of a Phase IIb trial of its CF candidate lenabasum (formerly anabasum). Corbus...
BioCentury | Jun 6, 2018
Company News

Ex-FDA official Jenkins joins Corbus' board

...disease company Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP). Jenkins joined FDA in 1992 and was OND's director from 2002-17. Corbus'...
...Phase II testing for systemic lupus erythematosus (SLE), cystic fibrosis and dermatomyositis. Allison Johnson Lenabasum (JBT-101, anabasum, resunab) Corbus Pharmaceuticals Holdings Inc. U.S...
BioCentury | Feb 10, 2018
Finance

Foundation validation

...behind a new approach to treating CF through a $25 million award to Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP). Corbus...
...regardless of cystic fibrosis transmembrane conductance regulator (CFTR) mutation. CFF initially awarded $5 million to Corbus...
...Yuval Cohen, Corbus Under the deal, CFF received warrants to purchase up to 1 million Corbus...
Items per page:
1 - 10 of 31
BioCentury | Sep 12, 2020
Product Development

Galapagos gains on Phase II win for systemic sclerosis candidate

...Data from the IPF trial are expected in 1H21. The systemic sclerosis readout comes days after Corbus Pharmaceuticals Holdings Inc....
...its primary and secondary endpoints in the Phase III RESOLVE-1 trial for the same indication. Corbus...
BioCentury | Sep 9, 2020
Product Development

Sept. 8 Quick Takes: Phase III wins for Albireo, Merck and Spero; plus Corbus, Blueprint, AnHeart, Grifols-Alkahest, and Exelixis-NBE

...to submit an NDA to FDA in 2Q21.Corbus’...
BioCentury | Jul 9, 2020
Management Tracks

Goeltz to join Arcus as CFO following Gilead deal; plus changes at Corbus, MyoKardia, Humanigen, Aimmune, Avrobio, Syndax and more

...in Gilead Deal” ). George Golumbeski joined the board of inflammatory and autoimmune diseases company Corbus Pharmaceuticals Holdings Inc....
BioCentury | Feb 1, 2019
Financial News

Corbus raises $35M follow-on

...Inflammatory and fibrotic diseases company Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) raised $35 million on Jan. 25 through the sale...
...10% discount to Corbus' close of $7.26 on Jan. 24, before the offering was announced. Corbus Pharmaceuticals Holdings Inc....
...close of $7.26 on Jan. 24, before the offering was announced. Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), Norwood, Mass. Shannon Lehnbeuter Corbus Pharmaceuticals Holdings Inc....
BioCentury | Sep 21, 2018
Company News

Corbus gets over 600 endocannabinoid-targeting compounds from Jenrin

...will receive $250,000 upfront and is eligible for $18.4 million in milestones for each compound Corbus...
...Jenrin will not research, develop or commercialize any compounds modulating cannabinoid receptors for 10 years. Corbus...
...and kidney diseases. Jenrin Discovery LLC, Chadds Ford, Pa. Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), Norwood, Mass. Business: Pharmaceuticals Jennie Walters Corbus Pharmaceuticals Holdings Inc. Jenrin...
BioCentury | Aug 11, 2018
Product Development

Exacerbation management

...Based on work spearheaded by the Cystic Fibrosis Foundation, Corbus Pharmaceuticals Holdings Inc. will be the first company to...
...FEV1) but did reduce the frequency of pulmonary exacerbations, the Cystic Fibrosis Foundation (CFF) suggested Corbus...
...gain in lung function is dramatic over the long term.” Yuval Cohen, Corbus Cohen said Corbus...
BioCentury | Aug 3, 2018
Clinical News

Celtaxsys planning Phase III program for CF candidate

...the North American Cystic Fibrosis Foundation meeting in Denver in October. In January, FDA gave Corbus Pharmaceuticals Holdings Inc....
...primary efficacy endpoint of a Phase IIb trial of its CF candidate lenabasum (formerly anabasum). Corbus...
BioCentury | Aug 2, 2018
Clinical News

Celtaxsys planning Phase III program for CF candidate

...the North American Cystic Fibrosis Foundation meeting in Denver in October. In January, FDA gave Corbus Pharmaceuticals Holdings Inc....
...primary efficacy endpoint of a Phase IIb trial of its CF candidate lenabasum (formerly anabasum). Corbus...
BioCentury | Jun 6, 2018
Company News

Ex-FDA official Jenkins joins Corbus' board

...disease company Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP). Jenkins joined FDA in 1992 and was OND's director from 2002-17. Corbus'...
...Phase II testing for systemic lupus erythematosus (SLE), cystic fibrosis and dermatomyositis. Allison Johnson Lenabasum (JBT-101, anabasum, resunab) Corbus Pharmaceuticals Holdings Inc. U.S...
BioCentury | Feb 10, 2018
Finance

Foundation validation

...behind a new approach to treating CF through a $25 million award to Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP). Corbus...
...regardless of cystic fibrosis transmembrane conductance regulator (CFTR) mutation. CFF initially awarded $5 million to Corbus...
...Yuval Cohen, Corbus Under the deal, CFF received warrants to purchase up to 1 million Corbus...
Items per page:
1 - 10 of 31